Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting (Companion Faculty Lecture)
Research To Practice | Oncology Videos · Dr. Neil Love
April 16, 202531m 10s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring a slide presentation and related discussion from Dr Raajit K Rampal, including the following topics:
- Overview of the current JAK inhibitor landscape (0:00)
- Factors predicting clinical benefit in patients with myelofibrosis (MF) receiving ruxolitinib (3:02)
- Clinical data supporting the use of fedratinib after prior ruxolitinib for MF (9:17)
- Emerging clinical findings on pelabresib in combination with ruxolitinib for previously untreated MF (12:13)
- Available clinical data with novel BET inhibitors (15:00)
- Utility of selinexor in combination with ruxolitinib for MF previously treated with ruxolitinib (16:50)
- Emerging efficacy and safety findings reported with imetelstat for MF (18:57)
- Clinical findings reported with the MDM2 inhibitor navtemadlin for MF (21:15)
- Available clinical data with the TGF-beta inhibitor elritercept for MF (24:05)
- Other novel agents and strategies under investigation for MF (26:06)